# Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

> **NCT06863376** · PHASE2 · RECRUITING · sponsor: **Tanta University** · enrollment: 46 (estimated)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Carbocysteine 375 MG
- **OTHER:** Physical activity, walking, and calorie restriction

## Key facts

- **NCT ID:** NCT06863376
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2027-03-20
- **Final completion:** 2027-04-20
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863376, "Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06863376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*